SUVEN PHARMACEUTICALS LTD Q3 RESULTS
RVNL among India Inc's unlucky 13 with over 25% drop in both sales, profit in Q1
To maintain a premium valuation, a stock must demonstrate strong earnings growth and a positive future outlook. However, the June quarter results revealed that several prominent companies, including popular retail multibaggers, fell short in terms of earnings. ETMarkets reviewed companies with an m-cap of at least Rs 5,000 crore and identified 13 entities that reported at least a 25% YoY decline in sales and profit.
Akum Drugs shares tumble 5% despite posting Rs 60 crore Q1 profit
Akum Drugs Share Price: Akum Drugs and Pharmaceuticals' shares dropped 5% to Rs 895 despite reporting a Rs 60 crore net profit for the June quarter, reversing a Rs 187.4 crore loss from FY24. Revenue also rose 5% YoY to Rs 1,091 crore.
India Inc: Key takeaways from Q1 results season
In Q1FY25, Bank and Auto stocks outperformed, while Infrastructure, Pharmaceuticals, and Metals lagged, resulting in modest 3% earnings growth. Revenue growth stayed at 9%. Real estate, pharmaceutical, and IT sectors highlighted notable revenue and profitability growth. Banks' NIMs remained stable, and auto sales surged, especially in two-wheelers and commercial vehicles.
Oil and gas spoil India Inc show in June Quarter
In the June 2024 quarter, India's industry saw modest growth with a 9.4% net profit increase, mainly due to lower refining and marketing margins in the oil and gas sector. Banking and finance sectors performed well with significant revenue growth. The overall operating margin declined to 17.4%. Future growth hinges on rural demand revival post-monsoon.
Zydus Lifesciences Q1 results: Net profit jumps 31% to Rs 1420 crore
The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 38.4% YoY to Rs 2084 crore. On QoQ, EBITDA increased 27.8%.
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
- Go To Page 1
Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540 basis points on y-o-y basis to 15.3%
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
Q1 results this week: ITC, SBI, TaMo, Zomato among 130 firms to announce earnings
This week, several prominent companies released their June quarter financial results. Firms like ITC, SBI, Adani Ports, Tata Motors, and M&M showcased their reports between July 29th and August 3rd. The updates offered a glimpse into their quarterly performance, engaging the attention of investors and stakeholders.
Q1 results, FII action among 10 factors to impact D-Street mood this week
Nifty gained 1.2%, driven by IT, energy, and pharma stocks. U.S. labor data, TCS earnings, Rupee vs. Dollar, Bank Nifty, oil prices, FIIs, IPO action, and dividends will influence markets next week. Bulls maintain strength with positive sentiment and broader market participation, expecting some consolidation.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Q4 results this week: Tata Steel, LIC, IRCTC, Apollo Hospitals Enterprise, and Bharat Dynamics
Several companies, including Tata Steel, LIC, and IRCTC, will release their March quarter report cards this week.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
GSK Pharma Q4 Results: Net profit rises 46% YoY at Rs 194.48 crore
The company had posted a net profit of Rs 133.43 crore in the corresponding quarter of the previous fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Lupin share price drops 5% post Q4 earnings
Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
PE Advent International queues up for a stake in Apollo 24/7
Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.
Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance Lifesciences
Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry position. After the merger, Advent entities will own 66.7%, and the transaction is expected to conclude in 12-15 months.
These 26 companies saw over 25% drop in Q3 sales, PAT; are they still worth betting on?
Around 26 companies, with a market capitalisation of over Rs 2,500 crore, reported atleast 25% year-on-year (YoY) fall in both revenue and profits in the last quarter, and a majority of them were part of the chemicals and pesticides sector.
Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic sales
Total revenue from operations declined to Rs 2,507 crore as compared with Rs 3,100 crore in the year-ago period, Glenmark Pharma said in a statement.
Divi’s Labs Q3 results today: Could there be any fireworks in the scorecard?
The consolidated net profit for the quarter is seen rising 33% YoY to Rs 407.40 crore, according to the average of estimates given by five brokerage firms.
Supriya Lifesciences Q3 Results: Net profit triples to Rs 30 crore
Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points.
Alembic Pharma posts Rs 180 crore net profit in Q3FY24
Drug maker Alembic Pharma on Monday reported Rs 180 crore net profit in Q3FY24, which is a 48% year-on-year (YoY) increase compared to the corresponding period of the previous year led by India and US sales growth.
Sun Pharma's steady Q3 earnings prompt target upgrades by brokerages. Should you buy?
The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price.
Q3 results today: Adani Enterprises, Adani Ports, Titan among 86 companies to announce earnings
The Street has an action-packed day on Thursday with the release of Union Budget 2024 and earnings announcements from 86 BSE listed companies for the December quarter. Notable companies to watch among the Nifty companies are Adani Enterprises, Adani Ports & Special Economic Zone, and Titan Company. Other important results include Abbott India, Aether, Bata India, Castrol India, Deepak Fertilizers and Petrochemicals Corporation, GMM PFaudler, India Cements, Jyothy Labs, Jupiter Wagons, Dr Lal Pathlabs, Minda Corp, MPhasis, RITES, Texmaco Rail & Engineering, Thyrocare.
Sun Pharma Q3 Results: Cons PAT rises 17% YoY to Rs 2,561 crore; Rs 8.5/sh dividend announced
Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined.
Sun Pharma Q3 results today: What to expect from India’s top drug maker?
Sun Pharma Q3 results: Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical's performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored.
Q3 results today: Maruti, Sun Pharma, Dabur among 113 companies to announce earnings
Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maruti Suzuki India is expected to report healthy revenue growth, while Sun Pharmaceuticals may see moderate revenue growth.
Load More
